Business Context and Reporting Period
This Form 6-K filing by Innate Pharma S.A., a foreign private issuer, covers the reporting period of May 2022. The document serves to incorporate by reference a press release dated May 20, 2022, into the company's registration statement on Form F-3.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. The document is a procedural filing referencing an external press release rather than a financial statement containing quantitative data.
Material Changes
No material financial changes or comparative period data are disclosed within the text of this filing. The content is limited to the incorporation of the referenced press release.
Guidance, Outlook, and Risks
The filing does not contain management commentary, guidance, outlook, or specific risk factors. It solely confirms the submission of the May 20, 2022, press release as Exhibit 99.1.
Investor Verification Checklist
- Review the full text of the press release dated May 20, 2022 (Exhibit 99.1) for the actual content of the announcement.
- Verify the details of the incorporation by reference into Form F-3 (File No. 333-252074).
- Confirm the identity of the signatory, Mondher Mahjoubi, as Chairman of the Executive Board and CEO.